Zobrazeno 1 - 10
of 988
pro vyhledávání: '"T-cell engager"'
Autor:
Shenxia Xie, Wei Shi, Siliang Duan, Xianing Huang, Aiqun Liu, Xiaoqiong Hou, Xuandong Lin, Dani Zhong, Shuyang Sun, Ziqiang Ding, Xiaomei Yang, Xiaoyuan Chen, Xiaoling Lu
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Background T cell-based immunotherapies are facing great challenges in the recruitment and activation of tumor-specific T cells against solid tumors. Among which, utilizing nanobody (Nb) or nanobodies (Nbs) to construct T cell engager has em
Externí odkaz:
https://doaj.org/article/34819bd0e84d4974b541afced7e0be7f
Autor:
Yi Zhang, Miso Park, Lucy Y. Ghoda, Dandan Zhao, Melissa Valerio, Ebtesam Nafie, Asaul Gonzalez, Kevin Ly, Bea Parcutela, Hyeran Choi, Xubo Gong, Fang Chen, Kaito Harada, Zhenhua Chen, Le Xuan Truong Nguyen, Flavia Pichiorri, Jianjun Chen, Joo Song, Stephen J. Forman, Idoroenyi Amanam, Bin Zhang, Jie Jin, John C. Williams, Guido Marcucci
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-18 (2024)
Abstract Background The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providing an opportunity to t
Externí odkaz:
https://doaj.org/article/81c6c4a1c88f4c5d9d2eee24813cc8c0
Autor:
Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, Yeh Chen, Jennifer Hui‐Chun Ho, Fang‐Yu Lin, Xiao‐Tong Tan, Hung‐Che Chiang, Chiu‐Ching Huang, Chih‑Yen Tu, Der‐Yang Cho, Shao‐Chih Chiu
Publikováno v:
Advanced Science, Vol 11, Iss 41, Pp n/a-n/a (2024)
Abstract Immunotherapy targeting immune checkpoints (ICPs), such as programmed death‐ligand‐1 (PD‐L1), is used as a treatment option for advanced or metastatic non‐small cell lung cancer (NSCLC). However, overall response rate to anti‐PD‐
Externí odkaz:
https://doaj.org/article/7864291b849244c5babdc5d7f746e0bd
Autor:
Lisa A. King, Milon de Jong, Myrthe Veth, David Lutje Hulsik, Parsa Yousefi, Victoria Iglesias-Guimarais, Pauline M. van Helden, Tanja D. de Gruijl, Hans J. van der Vliet
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundVγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the
Externí odkaz:
https://doaj.org/article/3eb04d8fffbe403ba273566ef54bbcbc
Autor:
William H. Robinson, David Fiorentino, Lorinda Chung, Larry W. Moreland, Malavika Deodhar, Mary Beth Harler, Carrie Saulsbery, Rebecca Kunder
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
B-cell depletion therapy (BCDT) has been employed to treat autoimmune disease for ~20 years. Immunoglobulin G1 (IgG1) monoclonal antibodies targeting CD20 and utilizing effector function (eg, antibody-dependent cellular cytotoxicity, complement-depen
Externí odkaz:
https://doaj.org/article/f6ca48ff0e614052bb2506a211f875af
Autor:
Fuxin Xue, Xitong Ren, Chaoying Kong, Jianfeng Wang, Linlin Liu, Junli Hu, Na Shen, Zhaohui Tang
Publikováno v:
Materials Today Bio, Vol 28, Iss , Pp 101239- (2024)
Immune checkpoint blockade (ICB) therapy, particularly PD1/PDL1 inhibition, has demonstrated success in bolstering durable responses in patients. However, the response rate remains below 30 %. In this study, we developed a polymeric bispecific antibo
Externí odkaz:
https://doaj.org/article/d8ac2ed7892c4d5c80a3a4054ee33766
Autor:
Shetal A. Patel, MD, PhD, Young Whang, MD, PhD, Chaely Medley, NP, Kevin Chen, PharmD, Jasmine Jordan, BS, Dante Bortone, PhD, Benjamin Vincent, MD, PhD, Jared Weiss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100712- (2024)
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulte
Externí odkaz:
https://doaj.org/article/8000f77d3fd64147a7f544962cd9ad9f
Autor:
Paula Rodriguez-Otero, Thomas Martin
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 171-179 (2024)
The treatment of relapsed and refractory multiple myeloma has improved substantially in the last 5–10 years based on the development and use of several novel classes of drugs and drug combinations. These advances have led to improvements in progres
Externí odkaz:
https://doaj.org/article/f1fcc3e73eef4e409a17047281c1673a
Autor:
Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li, Kai He
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-5 (2024)
Abstract DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeutic strategies targeting DLL3 are
Externí odkaz:
https://doaj.org/article/d10fc426c38f4600bcf76fa725a89e1b
Autor:
Kovac Milena Blaz, Seruga Bostjan
Publikováno v:
Radiology and Oncology, Vol 58, Iss 2, Pp 170-178 (2024)
Various types of immunotherapy (i.e. immune checkpoint inhibitors [ICIs], chimeric antigen receptor [CAR] T-cells and bispecific T-cell engagers [BiTEs]) and antibody drug conjugates (ADCs) have been used increasingly to treat solid cancers, lymphoma
Externí odkaz:
https://doaj.org/article/b1cc3e3d0d114890aa3c517c510bd9fe